{"id":1665,"date":"2024-10-11T19:36:56","date_gmt":"2024-10-11T19:36:56","guid":{"rendered":"https:\/\/www.saveuighur.org\/?p=1665"},"modified":"2024-10-17T14:23:21","modified_gmt":"2024-10-17T14:23:21","slug":"save-uyghur-campaign-urges-action-against-uyghur-forced-labor-in-pharmaceutical-supply-chains","status":"publish","type":"post","link":"https:\/\/www.saveuighur.org\/ug\/save-uyghur-campaign-urges-action-against-uyghur-forced-labor-in-pharmaceutical-supply-chains\/","title":{"rendered":"Justice For All\u2019s Save Uyghur Campaign Urges Action Against Uyghur Forced Labor in Pharmaceutical Supply Chains"},"content":{"rendered":"

Justice For All<\/span><\/a>\u2019s <\/span>Save Uyghur Campaign<\/span><\/a> commends <\/span>Mishel Kondi<\/span><\/a>, a human security analyst at <\/span>C4ADS<\/span><\/a>, for her recent report<\/a> that exposes troubling connections between the global pharmaceutical industry and the use of Uyghur forced labor in Chinese-occupied East Turkistan,\u00a0 also known by its colonial name, the Xinjiang Uyghur Autonomous Region (XUAR).<\/span><\/p>\n

The international community has condemned the Chinese Communist Party\u2019s repression against Uyghur and Turkic peoples that includes forced labor, mass detention and coercive labor practices. The U.S passed the Uyghur Forced Labor Prevention Act (UFLPA) in 2021, which aimed to block imports linked to forced labor in East Turkistan. Yet, Kondi\u2019s report draws attention to the ways in which the pharmaceutical industry in the Uyghur region \u201chas not been the focus of enforcement action to counter forced labor to date.\u201d<\/span><\/p>\n

Referring to \u201cdark data environments, complex supply chains, and policy implementation obstacles,\u201d the report argues that stakeholders are challenged to ensure their supply chains are free from forced labor and human rights violations. For instance, the report points out that companies such as Sinopharm and Xinjiang Deyuan Bioengineering Co., LTD, which are \u201ctied to human rights abuses \u2026\u00a0 remain part of global supply chains.\u201d So China\u2019s human rights abuses continue.<\/span><\/p>\n

The report also draws attention to India\u2019s important role in the global pharmaceutical supply chain. It notes India\u2019s pharmaceutical purchases from East Turkistan-based companies, such as the importation of over 150 thousand kilograms of conjugated estrogen in the first 3 months of 2024.<\/span><\/p>\n

Justice For All\u2019s Save Uyghur Campaign calls for increased transparency and accountability within the pharmaceutical sector. We echo the report\u2019s recommendations:<\/span><\/p>\n